Tango Therapeutics, Inc. - TNGX
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jun 03, 2026 | President, R&D | M | D | 27,000.0 | 0.0 | 0.0 | 341,040.0 | View | |
| Jun 03, 2026 | President, R&D | S | D | 20,860.0 | 23.0558 | 480,943.99 | 115,743.0 | View | |
| Jun 03, 2026 | President, R&D | S | D | 6,140.0 | 22.252 | 136,627.28 | 136,603.0 | View | |
| Jun 03, 2026 | President, R&D | M | A | 27,000.0 | 5.2 | 140,400.0 | 142,743.0 | View | |
| May 05, 2026 | President, R&D | M | D | 27,000.0 | 0.0 | 0.0 | 368,040.0 | View | |
| May 05, 2026 | President, R&D | S | D | 1,100.0 | 21.9964 | 24,196.04 | 115,743.0 | View | |
| May 05, 2026 | President, R&D | S | D | 25,900.0 | 21.1931 | 548,901.29 | 116,843.0 | View | |
| May 05, 2026 | President, R&D | M | A | 27,000.0 | 5.2 | 140,400.0 | 142,743.0 | View | |
| May 05, 2026 | Chief Financial Officer | A | A | 240,000.0 | 0.0 | 0.0 | 240,000.0 | View | |
| May 05, 2026 | Chief Financial Officer | A | A | 40,000.0 | 0.0 | 0.0 | 40,000.0 | View | |
| May 01, 2026 | — | A | A | 5,200.0 | 0.0 | 0.0 | 5,200.0 | View | |
| May 01, 2026 | — | A | A | 12,300.0 | 0.0 | 0.0 | 22,300.0 | View | |
| Apr 16, 2026 | President, R&D | M | D | 38,460.0 | 0.0 | 0.0 | 395,040.0 | View | |
| Apr 16, 2026 | President, R&D | S | D | 38,460.0 | 25.0 | 961,500.0 | 112,622.0 | View | |
| Apr 16, 2026 | President, R&D | M | A | 38,460.0 | 5.2 | 199,992.0 | 151,082.0 | View | |
| Apr 02, 2026 | President, R&D | M | D | 27,000.0 | 0.0 | 0.0 | 433,500.0 | View | |
| Apr 02, 2026 | President, R&D | S | D | 27,000.0 | 21.2029 | 572,478.3 | 112,622.0 | View | |
| Apr 02, 2026 | President, R&D | M | A | 27,000.0 | 5.2 | 140,400.0 | 139,622.0 | View | |
| Mar 27, 2026 | President, R&D | M | D | 12,000.0 | 0.0 | 0.0 | 460,500.0 | View | |
| Mar 27, 2026 | President, R&D | S | D | 12,000.0 | 20.11 | 241,320.0 | 112,622.0 | View | |
| Mar 27, 2026 | President, R&D | M | A | 12,000.0 | 5.2 | 62,400.0 | 124,622.0 | View | |
| Mar 09, 2026 | President, R&D | S | D | 20,251.0 | 15.0 | 303,765.0 | 112,622.0 | View | |
| Feb 27, 2026 | President, R&D | S | D | 54,345.0 | 12.7741 | 694,208.46 | 132,873.0 | View | |
| Feb 04, 2026 | Director, Executive Chair | A | A | 222,132.0 | 0.0 | 0.0 | 222,132.0 | View | |
| Feb 04, 2026 | Director, Executive Chair | S | D | 333.0 | 12.8971 | 4,294.73 | 1,629,254.0 | View | |
| Feb 04, 2026 | Director, Executive Chair | S | D | 30,186.0 | 12.2573 | 369,998.86 | 1,629,587.0 | View | |
| Feb 04, 2026 | Director, Executive Chair | A | A | 37,522.0 | 0.0 | 0.0 | 1,659,773.0 | View | |
| Feb 04, 2026 | Chief Financial Officer | A | A | 265,980.0 | 0.0 | 0.0 | 265,980.0 | View | |
| Feb 04, 2026 | Chief Financial Officer | S | D | 113.0 | 12.8971 | 1,457.37 | 184,297.0 | View | |
| Feb 04, 2026 | Chief Financial Officer | S | D | 10,204.0 | 12.2573 | 125,073.49 | 184,410.0 | View | |
| Feb 04, 2026 | Chief Financial Officer | A | A | 44,330.0 | 0.0 | 0.0 | 194,614.0 | View | |
| Feb 04, 2026 | President, R&D | A | A | 284,760.0 | 0.0 | 0.0 | 284,760.0 | View | |
| Feb 04, 2026 | President, R&D | S | D | 201.0 | 12.8971 | 2,592.32 | 187,218.0 | View | |
| Feb 04, 2026 | President, R&D | S | D | 18,251.0 | 12.2573 | 223,707.98 | 187,419.0 | View | |
| Feb 04, 2026 | President, R&D | A | A | 47,460.0 | 0.0 | 0.0 | 205,670.0 | View | |
| Jan 12, 2026 | President & CEO | A | A | 1,650,000.0 | 0.0 | 0.0 | 1,650,000.0 | View | |
| Jan 12, 2026 | President & CEO | A | A | 350,000.0 | 0.0 | 0.0 | 367,500.0 | View | |
| Jan 06, 2026 | — | A | A | 60,000.0 | 0.0 | 0.0 | 60,000.0 | View | |
| Jan 06, 2026 | — | A | A | 10,000.0 | 0.0 | 0.0 | 10,000.0 | View |